| Sheth, Veeral |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
| Recruiting | 2/3 | 497 | US | Dexamethasone ophthalmic suspension (OCS-01), Dexamethasone, Vehicle, Placebo | Oculis, ICON plc | Diabetic Macular Edema | 06/26 | 06/26 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Jager, Rama |
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial |
|
|
| Recruiting | 2 | 598 | US | STRI Formula, Placebo | Eyecheck, Inc. | Covid19 | 12/22 | 08/23 | | |
| Active, not recruiting | N/A | 11 | US | episcleral brachytherapy, Strontium 90 | Salutaris Medical Devices, Inc. | Macular Degeneration, Choroidal Neovascularization | 05/23 | 05/25 | | |
| Kirby, BreAnne |
Tejas, NCT05387837: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME |
|
|
| Active, not recruiting | 2 | 50 | US | D-4517.2, aflibercept | Ashvattha Therapeutics, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 11/24 | 12/24 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| Active, not recruiting | N/A | 11 | US | episcleral brachytherapy, Strontium 90 | Salutaris Medical Devices, Inc. | Macular Degeneration, Choroidal Neovascularization | 05/23 | 05/25 | | |
| Active, not recruiting | N/A | 95 | US | i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham | i-Lumen Scientific, Inc. | Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration | 06/25 | 06/25 | | |
| Learned, Daniel |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
